"Multicenter randomized clinical trial to evaluate the cardioverter capacity of amiodarone pre-electrical cardioversion in persistent atrial fibrillation"

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507201-34-00

Acronym

PERIVERSION

Enrollment

130

Registered

2024-08-30

Start date

2025-01-23

Completion date

Unknown

Last updated

2024-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial fibrillation

Brief summary

Efficacy of amiodarone in reversion to sinus rhythm before electrical cardioversion in persistent atrial fibrillation.

Detailed description

1) time from initiation of amiodarone to reversion to sinus rhythm; 2) maintenance of sinus rhythm during the month after electrical cardioversion.

Interventions

DRUGTrangorex 200 mg comprimidos

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Efficacy of amiodarone in reversion to sinus rhythm before electrical cardioversion in persistent atrial fibrillation.	—

Secondary

Measure	Time frame
1) time from initiation of amiodarone to reversion to sinus rhythm; 2) maintenance of sinus rhythm during the month after electrical cardioversion.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026